UK's Poor Uptake Of New Drugs May Be Hitting Clinical Trial Investment
The pharmaceutical industry wants the UK to improve its uptake of innovative medicines in order to spur investment in clinical trials under the government's life sciences sector deal. One industry representative says companies are already questioning the ethics of conducting trials in a country where their drug might not be commercialized.
You may also be interested in...
Some of the loudest messages from UK government's Life Science Sector Deal was the importance of using real world evidence - and the uniqueness the British health ecosystem can offer to trail blazing innovation.
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.